Pharmacoeconomic review report: Empagliflozin (Jardiance)
Empagliflozin (Jardiance) is a once-daily oral antidiabetic drug belonging to the sodium glucose cotransporter-2 (SGLT-2) inhibitor class. It promotes urinary glucose excretion. This review by the CADTH Common Drug Review (CDR) will focus on the following indication: 1. For adults with type 2 diabet...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
October 2015, 2015
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references